Abstract
Context: Humans respond profoundly to changes in diet, while nutrition and environment have a great impact on population health. It is therefore important to deeply characterize the human nutritional responses. Objective: Endocrine parameters and the metabolome of human plasma are rapidly responding to acute nutritional interventions such as caloric restriction or a glucose challenge. It is less well understood whether the plasma proteome would be equally dynamic, and whether it could be a source of corresponding biomarkers. Methods: We used high-throughput mass spectrometry to determine changes in the plasma proteome of i) 10 healthy, young, male individuals in response to 2 days of acute caloric restriction followed by refeeding; ii) 200 individuals of the Ely epidemiological study before and after a glucose tolerance test at 4 time points (0, 30, 60, 120 minutes); and iii) 200 random individuals from the Generation Scotland study. We compared the proteomic changes detected with metabolome data and endocrine parameters. Results: Both caloric restriction and the glucose challenge substantially impacted the plasma proteome. Proteins responded across individuals or in an individual-specific manner. We identified nutrient-responsive plasma proteins that correlate with changes in the metabolome, as well as with endocrine parameters. In particular, our study highlights the role of apolipoprotein C1 (APOC1), a small, understudied apolipoprotein that was affected by caloric restriction and dominated the response to glucose consumption and differed in abundance between individuals with and without type 2 diabetes. Conclusion: Our study identifies APOC1 as a dominant nutritional responder in humans and highlights the interdependency of acute nutritional response proteins and the endocrine system.
Original language | English |
---|---|
Pages (from-to) | 2087-2098 |
Number of pages | 12 |
Journal | The Journal of clinical endocrinology and metabolism |
Volume | 108 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2023 |
Funding
Work at the M.R. lab was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and the Wellcome Trust (FC001134, IA 200829/Z/16/Z). This research was funded in part by the European Research Council (ERC) under grant agreement ERC-SyG-2020 951475 (to M.R.), the Wellcome Trust (FC001134 and IA 200829/Z/16/Z to M.R.) and by the German Ministry of Education and Research (BMBF), as part of the National Research Node \u201CMass spectrometry in Systems Medicine (MSCoreSys)\u201D, under grant agreements 031L0220 to M.R. and 161L0221 to V.D. C.H. was supported by an MRC Human Genetics Unit programme grant \u201CQuantitative traits in health and disease\u201D (U. MC_UU_00007/10). T.H.C.\u2019s research is supported by grants from the Swiss National Science Foundation, the Leenaards Foundation, the Vontobel Foundation, the Medical Board of the Geneva University Hospitals, the Nutrition 2000plus Foundation, and the Swiss Society of Endocrinology and Diabetes. A.Z. was supported by SciLifeLab funding and the Marius Jakulis Jason Foundation. I.S.F. was supported by the Wellcome Trust (207462/Z/17/Z), the NIHR (National Institute for Health Research) Cambridge Biomedical Research Centre, Fondation Botnar, the Bernard Wolfe Health Neuroscience Endowment, and a NIHR Senior Investigator Award. The funding bodies had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Computing resources at the Chalmers Center for Computational Science and Engineering (C3SE) were partially funded by the Swedish Research Council through grant agreement no. 2018-05973 (A.Z.). NJW and CL were supported by the Medical Research Council (MC_UU_00006/1).
Keywords
- APOC1
- caloric restriction
- oral glucose tolerance test
- plasma proteomics
- type 2 diabetes